Literature DB >> 24820211

Recovery from life-threatening transplantation-associated thrombotic microangiopathy using eculizumab in a patient with very severe aplastic anemia.

M Okano1, N Sakata1, S Ueda1, T Takemura1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24820211     DOI： 10.1038/bmt.2014.97

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  8 in total

1.  Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation.

Authors:  Hirohisa Nakamae; Takahisa Yamane; Taro Hasegawa; Mika Nakamae; Yoshiki Terada; Kiyoyuki Hagihara; Kensuke Ohta; Masayuki Hino
Journal:  Am J Hematol       Date:  2006-07       Impact factor: 10.047

2.  Successful use of eculizumab in a patient with post-transplant thrombotic microangiopathy.

Authors:  Régis Peffault de Latour; Aliénor Xhaard; Véronique Fremeaux-Bacchi; Paul Coppo; Anne Marie Fischer; Dominique Helley; Gérard Socié
Journal:  Br J Haematol       Date:  2013-01-07       Impact factor: 6.998

Review 3.  Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation.

Authors:  Vincent T Ho; Corey Cutler; Shelly Carter; Paul Martin; Roberta Adams; Mary Horowitz; James Ferrara; Robert Soiffer; Sergio Giralt
Journal:  Biol Blood Marrow Transplant       Date:  2005-08       Impact factor: 5.742

Review 4.  Treatment of atypical hemolytic uremic syndrome and thrombotic microangiopathies: a focus on eculizumab.

Authors:  Jan Schmidtko; Sven Peine; Youssef El-Housseini; Manuel Pascual; Pascal Meier
Journal:  Am J Kidney Dis       Date:  2012-11-07       Impact factor: 8.860

5.  Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome.

Authors:  Iain Moore; Lisa Strain; Isabel Pappworth; David Kavanagh; Paul N Barlow; Andrew P Herbert; Christoph Q Schmidt; Scott J Staniforth; Lucy V Holmes; Roy Ward; Lynn Morgan; Timothy H J Goodship; Kevin J Marchbank
Journal:  Blood       Date:  2009-10-27       Impact factor: 22.113

6.  Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria.

Authors:  Peter Hillmen; Claire Hall; Judith C W Marsh; Modupe Elebute; Michael P Bombara; Beth E Petro; Matthew J Cullen; Stephen J Richards; Scott A Rollins; Christopher F Mojcik; Russell P Rother
Journal:  N Engl J Med       Date:  2004-02-05       Impact factor: 91.245

Review 7.  Thrombotic microangiopathy in haematopoietic stem cell transplantation: diagnosis and treatment.

Authors:  Cecilia M Choi; Alvin H Schmaier; Michael R Snell; Hillard M Lazarus
Journal:  Drugs       Date:  2009       Impact factor: 9.546

8.  Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy.

Authors:  Sonata Jodele; Christoph Licht; Jens Goebel; Bradley P Dixon; Kejian Zhang; Theru A Sivakumaran; Stella M Davies; Fred G Pluthero; Lily Lu; Benjamin L Laskin
Journal:  Blood       Date:  2013-06-27       Impact factor: 22.113
  8 in total
  7 in total

1.  Severe, persistent neurotoxicity after transplant-associated thrombotic microangiopathy in a pediatric patient despite treatment with eculizumab.

Authors:  Michelle Schoettler; Christine Duncan; Leslie Lehmann
Journal:  Pediatr Transplant       Date:  2019-03-03

2.  Case Report: Successful Treatment With Anti-C5 Monoclonal Antibody in a Japanese Adolescent Who Developed Thrombotic Microangiopathy After Autologous Bone Marrow Transplantation for Malignant Lymphoma.

Authors:  Shoichi Shimizu; Tamaki Morohashi; Koji Kanezawa; Hiroshi Yagasaki; Shori Takahashi; Ichiro Morioka
Journal:  Front Pediatr       Date:  2022-07-04       Impact factor: 3.569

3.  Risk factors for transplant-associated thrombotic microangiopathy and mortality in a pediatric cohort.

Authors:  Michelle Schoettler; Leslie E Lehmann; Steven Margossian; Maia Lee; Leslie S Kean; Pei-Chi Kao; Clement Ma; Christine N Duncan
Journal:  Blood Adv       Date:  2020-06-09

4.  Transplant-associated Thrombotic Microangiopathy Treated with Eculizumab and Romiplostim.

Authors:  Muhammad Awidi; Meenu Jain; Russell Baur
Journal:  Eur J Case Rep Intern Med       Date:  2021-02-10

5.  Efficacy and Safety of Eculizumab in the Treatment of Transplant-Associated Thrombotic Microangiopathy: A Systematic Review and Meta-Analysis.

Authors:  Rui Zhang; Meng Zhou; Jiaqian Qi; Wenjing Miao; Ziyan Zhang; Depei Wu; Yue Han
Journal:  Front Immunol       Date:  2021-01-20       Impact factor: 7.561

6.  Eculizumab Treatment in a Patient with Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy and Steroid-Refractory Acute Graft Versus Host Disease.

Authors:  Cristina Fernández; Ana Lario; Rafael Forés; Rafael Cabrera
Journal:  Hematol Rep       Date:  2015-12-09

7.  Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea.

Authors:  Vicky Brocklebank; David Kavanagh
Journal:  Clin Kidney J       Date:  2017-05-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.